|
|
Hainan, China, December 13, 2007
Dr. Gadi Aharoni, CEO of digital signature solutions provider, ARX, will join other life science industry leaders for a week long training session for the Chinese State Food and Drug Administration (SFDA) and other stakeholders in the growing Chinese pharmaceutical supply marketplace. The event will be held December 15-19, 2007 in Hainan, China.
The event focuses on Good Clinical Practice (GCP) compliance and related GxP topics, such as good documentation best practices, preparation for regulatory audits, and current technology trends particularly in the clinical trial space. Dr. Aharoni will discuss the best practice of using digital signatures (standard electronic signatures) within an enterprise or even cross enterprise-wide strategy for regulatory compliance and other tangible business benefits such as expedited processes, reduced operational costs, and the added value of “going green” with paperless operations.
The timing of this event follows a year marked by well-publicized food and drug safety concerns that have damaged China’s credibility on the international stage. In the past year, the Chinese SFDA has revoked licenses of several drug manufacturers and has also withdrawn the Good Manufacturing Practice (GMP) certificates from over 100 drug makers, greatly reducing their capability to export active pharmaceutical ingredients (APIs) to the rest of the world. This past summer Zheng Xiaoyu, former director of SFDA, was sentenced to death by a Beijing court citing dereliction of duty as one of numerous charges against him.
The SFDA is now expanding the number of GMP inspectors in pharmaceutical factories and monitoring the production quality of drug manufacturers across the country. The SFDA Training event is another step towards educating the Chinese food and pharmaceutical market on the best practices and technology trends – such as the use of digital signatures - in other parts of the world.
The sponsors for this event include many recognized industry thought leaders with expertise in GxP and related technology strategies. Dr. Aharoni was recognized in 2006 as one of the Top 100 Influencers by readers of PharmaVoice, and ARX is recognized as a leading digital signature solutions provider within the life sciences sector. |
|
About CoSign Digital Signatures
ARX (Algorithmic Research) is a global provider of cost-efficient digital signature solutions for industries such as AEC, life sciences, healthcare, government, energy, and manufacturing. ARX CoSign® is the market leading digital signature solution. CoSign digital signatures fully automate signature-dependent processes affordably and compliantly, allowing organizations to go paperless and save time and money. Compatible with major document types including Word, Excel®, PDF, PDF/A, and IBM Forms, CoSign signatures are globally verifiable without requiring proprietary validation software. CoSign is also centrally managed by your organization for reliable control over signature privileges. Learn more about the CoSign digital signature solution.
|
|
About ARX - The Digital Signature Company
ARX (Algorithmic Research) is a global provider of cost-efficient digital signature solutions for industries such as life sciences, healthcare, government, engineering, and energy. ARX engineers and scientists have more than 20 years of experience in security and standard digital signature applications. ARX helps businesses secure, streamline, and scale their processes and transactions with the proper controls required by legislation, regulation, and industry best practices. Learn more about us.
|
|
###
CoSign is a registered trademark of Algorithmic Research, Ltd. All other trade names and trademarks are the property of their respective holders.
|
|
|
|
|
|
|
|
